Cees de Wolff

SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

Vereniging Aegon NV operates as holding firm, which engages in the provision of financial services. The company was founded in 1978 and is headquartered in The Hague, the Netherlands.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

Organon Teknika BV manufactures HIV diagnostic products, including NucliSens HIV-1 viral load and nucliSens HIV-1 RNA detection assays. The company is headquartered in Boxtel, the Netherlands.

MSD Oss BV manufactures active pharmaceutical ingredients. Its product line includes progestagens, estrogens and androgens that are used in contraceptives, hormone therapy and infertility treatment. The company also manufactures various chemicals, such as steroids, opioid analogues and synthetic peptides. It was founded in 1923 and is headquartered in Oss, the Netherlands.

PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium.

Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium.

Part of Syneos Health, Inc., NDDO Oncology BV provides product development support to pharmaceutical and biotechnology companies. The company is based in Amsterdam, Netherlands. The Dutch company was founded by Herbert Michael Pinedo. NDDO Oncology was acquired by Syneos Health NC LLC, part of Syneos Health, Inc. from December 31, 2010 on December 01, 2005.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning.

The Royal Society of Medicine provides postgraduate medical education. The Society provides a range of educational activities and opportunities for doctors, dentists and veterinary surgeons, including students, and for allied healthcare professionals. It also promotes an exchange of information and ideas on the science, practice and organization of medicine, both within the health professions and with responsible and informed public opinion. The Society was founded in 1805 and is headquartered in London, the United Kingdom.

BioX Biosciences BV (BioX) is an privately owned venture capital firm with its headquarters in s-Hertogenbosch, The Netherlands. The firm was established in 1983.

Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands.

The European Society for Medical Oncology (ESMO) is a leading medical oncology society that provides a professional network for its members and works with national societies across Europe. The non-profit company is based in Lugano, Switzerland. ESMO's position on a wide range of legislative and non-legislative policy files on both EU and levels is available to learn about. Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team. ESMO's Young Oncologists Corner is dedicated to providing educational and networking opportunities for medical oncologists under 40.

Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009.

VitrOmics Healthcare Holding BV is a holding company, which engages in the development of new diagnostic products based on the PamChip technology platform. Its platform is used for academic and bio-pharmaceutical research applications. The company was founded by Tim Kievits and is headquartered in 's-Hertogenbosch, the Netherlands.

Newtricious BV develops active food ingredients and products for health maintenance. It focuses on health areas, such as, obesity, metabolic syndrome, eye health, cardiovascular health, and diabetes. The company was founded by Jos Nelissen and Marieëtte Nelissen in 2006 and is headquartered in Oirlo, the Netherlands.

Neurophyxia BV develops 2-iminobiotin novel injectable pharmaceutical products. Its pharmaceutical products reduce the deleterious effects of oxygen shortage in the brain occurring in two life threatening conditions: Cardiac arrest and Birth asphyxia. The company was founded by Paul Willem Theresia Josef Leufkens, Cacha Peeters-Scholte and Huibert Tjabbes in 2008 and is headquartered in 's-Hertogenbosch, the Netherlands.

Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally.

Foundry Innovation & Research 1 Ltd. develops novel therapeutic devices. It has evolved into one of the leading clusters for medical devices globally. The company was headquartered in Dublin, Ireland.

Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands.

ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland.

EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.